Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2018

View Archived Issues

Corvus Pharmaceuticals initiates phase I study of CPI-006 in patients with advanced solid tumors

Phase III study evaluates ASTX-727 versus intravenous decitabine in patients with MDS and CMML

Immunic initiates phase III CALDOSE-1 study of IMU-838

Triple combination program for the treatment of cystic fibrosis receives FDA fast track designation

Novel orally bioavailable rohitukine derivative shows promise in xenograft cancer models

FDA and EMA accept regulatory submissions for dacomitinib

Phase III REACH-2 study of Cyramza meets primary endpoint

Roche acquires Inception neuroscience program from Versant Ventures

PLA2-R is a potential diagnostic marker of salivary gland tumors

Q-State Biosciences enters drug discovery collaboration with Vertex

Boehringer Ingelheim and OSE sign collaboration and license agreement for OSE-172

BB100 licenses MAbs targeting E. coli from Arsanis

Omigapil completes first clinical trial in patients with congenital muscular dystrophy

Conatus reports topline results from phase IIb POLT-HCV-SVR study of emricasan

PELP-1 mediates adverse response to endocrine therapy for ER-positive breast cancer

FDA grants orphan drug designation for MAX-40279 for the treatment of AML

FDA grants priority review to NDAs for omadacycline for CABP and ABSSSI

FDA allows IND for phase Ib/IIa study of AG-019 for early onset type 1 diabetes

Novel gene fusion detected in BCR-ABL-negative leukemia

Lilly and Sigilon collaborate on encapsulated cell therapies for type 1 diabetes

Kymera and GSK collaborate to accelerate discovery of protein-degrading therapeutics

A*STAR identifies novel MSP receptor-targeting antibodies

Pliant Therapeutics patents new integrin alphavbeta1 antagonists

Abide Therapeutics discovers MGL and ABHD6 inhibitors

Phase I trial studies BMS-986299 alone and with nivolumab and ipilimumab in advanced solid tumors

Novartis studies CLL-442 in cutaneous squamous cell carcinoma in situ

IGF Oncology studies 765-IGF-MTX in MDS, CMML and oligoblastic AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...